Document Detail


Prognostic Importance of 18F-FDG Uptake Pattern of Hepatocellular Cancer Patients Who Received SIRT.
MedLine Citation:
PMID:  23531737     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: The aim of the study was to evaluate the effect of F-FDG uptake pattern of liver lesions to treatment response of patients who received yttrium-90 (Y-90) selective internal radiation therapy (SIRT) for hepatocellular cancer (HCC). PATIENTS AND METHODS: Nineteen patients (5F, 14M, mean age: 64.5 ± 14.7 years old, range: 57-73 years) who received SIRT treatment in our department for HCC between June 2008 and May 2011 were included in the study. All patients underwent F-FDG PET/CT before SIRT for evaluation of disease stage and metabolic activity of liver lesions. Patients were divided into 3 groups according to FDG uptake patterns of primary liver lesions (hypoactive, nonhomogenous, and focal intense). Progression-free survival (PFS) times of each group and patients with hepatic only and hepatic with extrahepatic disease were analyzed. Disease progression criteria were increase in tumor volume, progressive elevation of serum alpha-fetoprotein levels, and detection of extrahepatic metastases. Kaplan-Meier analysis was used for comparison of PFS times. RESULTS: The mean treatment dose was calculated as 1.4 ± 1.0 GBq. While liver lesions of 4 patients were hypoactive in pretreatment F-FDG PET/CT, liver lesions of 6 and 9 patients had nonhomogenous and intense FDG uptake, respectively. Mean PFS time of patients who had hypoactive liver lesions was 5.25 ± 1.52 months. In patients who had liver lesions with nonhomogenous uptake, mean PFS time was 12.3 ± 2.6 months. Lastly, in patients with intense uptake in liver lesions, PFS time was calculated as 19.8 ± 5.0 months. Difference between each group was statistically significant (P = 0.017). There was no significant difference in the PFS of the patients with limited hepatic disease and patients with extrahepatic involvement. CONCLUSION: In patients with unresectable HCC, higher SUVmax lesions unexpectedly had better PFS rates after SIRT, suggesting SIRT has a treatment advantage over other therapeutic options in these patients.
Authors:
Ozlem N Kucuk; Cigdem Soydal; Mine Araz; Sadik Bilgic; Erkan Ibis
Related Documents :
24752347 - Anca-associated vasculitis in hispanic americans: an unrecognized severity.
24704387 - Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease.
23420517 - Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
24077647 - Carotid intima media thickness, oxidative stress, and inflammation in children with chr...
22951187 - Oxidative stress parameters in serum and low density lipoproteins of hashimoto's thyroi...
7382527 - Predisposing factors of renal dysfunction following total correction of tetralogy of fa...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-3-22
Journal Detail:
Title:  Clinical nuclear medicine     Volume:  -     ISSN:  1536-0229     ISO Abbreviation:  Clin Nucl Med     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-3-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7611109     Medline TA:  Clin Nucl Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
From the *Departments of Nuclear Medicine and †Radiology, Ankara University Medical School, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Classical Skeletal Injuries Shown on 18F-FDG PET/CT Following Successful Cardiopulmonary Resuscitati...
Next Document:  Usefulness of SPECT/CT for Equivocal Findings on 131I Whole-Body Scan in a Patient With Differentiat...